Marksans Pharma’s UK arm gets MHRA nod for pain-relief tablets

Marksans Pharma’s fully owned UK subsidiary, Relonchem Limited, has received authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to market Mefenamic Acid Film-Coated

Tablets in 250 mg and 500 mg strengths.

The drug is used for short-term relief of mild to moderate pain, including menstrual pain, and the approval expands the company’s offerings in the UK generics market.

Marksans Pharma, headquartered in Mumbai, is engaged in research, manufacturing, and global marketing of generic pharmaceutical formulations.

Following the announcement, shares opened at ₹194.80 and climbed to an intraday high of ₹198.99 before.

Also read: Groww market cap hits ₹1 lakh crore, stock now up 64% from IPO price

Earlier, the company reported a net profit of ₹98.2 crore for the September quarter, up 1.5% from a year ago. Revenue grew 12% year-on-year to ₹720 crore, supported by steady demand. EBITDA, however, declined 1.7% to ₹144.7 crore, with margins contracting to 20% from 23%.

Marksans’ UK and Europe businesses generated ₹245.3 crore in Q2 FY26. Despite pricing pressure, the company met its revenue and margin targets. With new filings and approvals such as the latest MHRA nod, its UK growth outlook remains favourable.

Also read: Gold prices ease in India as global markets await key US data